Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Clinical trial NCT05848219 · TERMINATED

Trial details

NCT number: NCT05848219
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Study type: OBSERVATIONAL

Metastatic Melanoma

Start date: 2021-10-16
Primary completion: 2022-04-27
Enrollment: 543

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.